EUCTR2016-001515-20-IT进行中（未招募）1 期
EFFECT OF TERIFLUNOMIDE ON T CELL SUBPOPULATIONS INPERIPHERAL BLOOD FROM RRMS PATIENTS - nd
IVERSITÀ CATTOLICA DEL SACRO CUORE- POLICLINICO A. GEMELLI0 个研究点目标入组 30 人开始时间: 2018年2月7日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients of male or female aged> 18 years, with relapsing remitting multiple sclerosis diagnosed according to the McDonald criteria 2010. Only patients candidates to treatment with teriflunomide will be enrolled
- •Aged between 18-55 years
- •EDSS between 0-5,5
- •Patients relapse free for = 30 days prior to study entry
- •No treatment with immunomodulatory drugs in the last 3 months
- •Ability to provide written informed consent and be compliant with the timing of the evaluations required by the Protocol
- •Women of childbearing potential and not complianti highly effective contraceptive measures defined in accordance with the recommendations of the Clinical Trial Facilitation Group (http://www.hma.eu/fileadmin/dateien/Human_Medicines/01About_HMA/Working_Groups/CTFG/2014_09_HMA_CTFG_Contraception.pdf)
- •Male patients with partners of childbearing age who do not belong to highly effective contraceptive measures defined in accordance with the recommendations of Clinical Trial Facilitation Group
- •Women who are pregnant or breast-feeding (in all women of childbearing age before you start treatment with Teriflunomide will be made the dosage of beta-HCG in serum, and also will be made a urinary pregnancy test every month during treatment as required by the recommendations of the Clinical Trial Facilitation Group)
- •Highly effective contraceptive measures under specific CTFG the recommendations are as follows:
- •-patients who use combined hormonal contraceptives (containing estrogen and progesterone) associated with inhibition of ovulation or oral, intravaginal that transdermal
- •- Patients who use hormonal contraceptives based only progesterone that inhibit ovulation, whether oral, injectable or implantable
- •- Patients with placement of IUD (intrauterine device)
- •-patients with positioning of hormone releasing intrauterine systems
- •- Patients with bilateral tubal occlusion
- •- Patients with vasectomized partner
- •- Patients who practice sexual abstinence
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 1
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 30
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •<18 years of age; > 55 years of age.
- •Patients diagnosed with progressive multiple sclerosis
- •Onset of disease relapse or treatment with corticosteroids within 30 days prior to study entry
- •Hypersensitivity to the active substance or to any of the excipients
- •Patients with severe hepatic impairment (Child-Pugh Class C).
- •Patients with pre-existing acute or chronic liver disease, or patients with levels of ALT (alanine aminotransferase) greater than 2 times the upper normal limit ULN).
- •Women of childbearing potential and not compliant to highly effective contraceptive measures defined in accordance with the recommendations of the Clinical Trial Facilitation Group(http://www.hma.eu/fileadmin/dateien/Human_Medicines/01About_HMA/Working_Groups/CTFG/2014_09_HMA_CTFG_Contraception.pdf). A ll women of childbearing age before starting treatment with teriflunomide it will be made the dosage of beta-HCG in serum; Also a urine pregnancy test will be performed monthly during treatment as provided by the recommendations of the Clinical Trial Facilitation Group)
- •Women lactating
- •Male patients with partners of childbearing age and not complianti highly effective contraceptive measures defined in accordance with the recommendations of the Clinical Trial Facilitation Group
- •Patients with severe immunodeficiency, such as AIDS (the determination of IgG and IgM serology for HIV type 1 and 2 will be conducted prior to initiating treatment with teriflunomide)
- •Any patients with severe active infection until resolution.
- •Patients with latent or active tuberculosis (before starting treatment with teriflunomide will be assayed the Quantiferon test)
- •Patients with severe renal failure requiring dialysis, there are not adequate clinical experience in this patient group.
- •Patients with significantly impaired bone marrow function or with anemia, leucopenia, neutropenia or thrombocytopenia.
- •Patients with severe hypoproteinaemia, eg nephrotic syndrome.
- •Previous course of treatment with teriflunomide.
- •Previous treatment with leflunomide (within 6 months prior to baseline).
- •Concomitant treatment with other immunosuppressive drugs
- •Medical or psychiatric conditions that compromise the patient's ability to give informed consent, to comply with the evaluation required under the Protocol or to complete the study.
- •diagnosis of dementia
- •history of malignancy, including solid tumors and hematologic malignancies
- •History or laboratory evidence of coagulation disorders
- •Patients with history or known presence of HBV infection, HCV (before starting treatment with teriflunomide should be performed the following serological tests: HBsAg, HBcAb confirmed by a positive research of HBV-DNA by PCR, anti HCV antibodies).
- •Patients with history or known presence of syphilis (in the period of screening will be carried out serological tests to determine anti-VDRL antibodies)
- •Comorbid for other neurological disorders that may mimic multiple sclerosis as neuromyelitis optica, Lyme disease, vitamin B12 deficiency is not treated, neurosarcoidosis and cerebrovascular disorders
- •abuse of alcohol or drugs.
- •Any contraindication to perform the Nuclear Magnetic Resonance such as: patients with cardiac pacemakers, insulin infusion pump, medication infusion device, cochlear implants, otological implants, transdermal patch of medications (nitro, hormones), which can cause problems if removed, even temporarily, any metal implants or objects piercing (s), bearers of screws, nails, bone plates, wire
研究者
相似试验
招募中
3 期
The safety and effect of Teriflunomide in patients with HTLV-1-induced myelopathyIRCT20180618040127N3Mashhad University of Medical Sciences22
招募中
不适用
In-vivo Bioequivalence Test of Teriflunomide® tablet with brand drugs (AUBAGIO® 14 mg Genzyme, Germany).IRCT20200105046010N25Aburayhan Pharmaceutical Company24
招募中
不适用
In-vivo Bioequivalence Test of Teriflunomide tablets with brand drug (AUBAGIO® 14 mg, Genzyme, Germany)Bio equivalence test.IRCT20200105046010N47Abidi Pharmaceutical Company24
终止
不适用
Teriflunomide's Therapeutic Mechanisms of Action in Patients With Relapsing Remitting Multiple Sclerosis.RELAPSING REMITTING MULTIPLE SCLEROSISNCT02833714University of North Carolina, Chapel Hill26
已完成
3 期
Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple SclerosisMultiple SclerosisNCT02201108Genzyme, a Sanofi Company166